The Amyloid-β Oligomer Hypothesis: Beginning of the Third Decade
Open accessThe DOI matches its Crossref record; 452 of the 457 references it cites were found in a registry or an index.
Abstract
The amyloid-β oligomer (AβO) hypothesis was introduced in 1998. It proposed that the brain damage leading to Alzheimer's disease (AD) was instigated by soluble, ligand-like AβOs. This hypothesis was based on the discovery that fibril-free synthetic preparations of AβOs were potent CNS neurotoxins that rapidly inhibited long-term potentiation and, with time, caused selective nerve cell death (Lambert et al., 1998). The mechanism was attributed to disrupted signaling involving the tyrosine-protein kinase Fyn, mediated by an unknown toxin receptor. Over 4,000 articles concerning AβOs have been published since then, including more than 400 reviews. AβOs have been shown to accumulate in an AD-dependent manner in human and animal model brain tissue and, experimentally, to impair learning and memory and instigate major facets of AD neuropathology, including tau pathology, synapse deterioration and loss, inflammation, and oxidative damage. As reviewed by Hayden and Teplow in 2013, the AβO hypothesis "has all but supplanted the amyloid cascade." Despite the emerging understanding of the role played by AβOs in AD pathogenesis, AβOs have not yet received the clinical attention given to amyloid plaques, which have been at the core of major attempts at therapeutics and diagnostics but are no longer regarded as the most pathogenic form of Aβ. However, if the momentum of AβO research continues, particularly efforts to elucidate key aspects of structure, a clear path to a successful disease modifying therapy can be envisioned. Ensuring that lessons learned from recent, late-stage clinical failures are applied appropriately throughout therapeutic development will further enable the likelihood of a successful therapy in the near-term.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig.1 AβOs, not Aβ monomers or fibrils, instigate the neuron damage leading to dementia. Following cleavage from the membrane, Aβ peptides aggregate to form AβOs, some of which further aggregate to fibrils and some of which instigate the neuron damage leading to dementia. Reprinted with Jannis Productions permissions from the “Progress Report on Alzheimer’s Disease 2004-2005” (ed. AB Rodgers), NIH Publication Number: 05-5724. Digital images produced by Stacy Jannis and Rebekah Fredenburg of Jannis Productions [455].](https://figures.cochat.ai/paper-figures/f6b42a17775e4881b942c99d83b0c0fa/the-amyloid-oligomer-hypothesis-beginning-of-the-third-decade-figure-1.jpg)
![Fig.2 AβOs instigate multiple facets of AD-neuropathology. Observed in various culture and animal models. Reprinted by permission from Springer Nature: Acta Neuropathol, 129(2): 183-206, “Amyloid beta oligomers in Alzheimer’s disease pathogenesis, treatment, and diagnosis” by Viola KL and Klein WL. Copyright 2015 Springer Nature [200].](https://figures.cochat.ai/paper-figures/4c12da5f31934b84a9263cc86d9b1ffd/the-amyloid-oligomer-hypothesis-beginning-of-the-third-decade-figure-2.jpg)

![Fig.4 AβOs can be divided into two classes based on their temporal, spatial, and structural relationships to amyloid plaques as well as their ability to cause memory dysfunction. Type 1 AβOs (aka “peak 1” or HMW) are thought to be associated with memory impairment, while type 2 AβOs (aka “peak 2” or LMW) are not. Only type 2 AβOs are associated with amyloid plaques. Reprinted from “Quaternary Structure Defines a Large Class of Amyloid-beta Oligomers Neutralized by Sequestration” by Liu P, Reed MN, Kotilinek LA, Grant MK, Forster CL, Qiang W, Shapiro SL, Reichl JH, Chiang AC, Jankowsky JL, Wilmot CM, Cleary JP, Zahs KR, and Ashe KH. This was published in Cell Rep, 2015, 11(11): 1760-1771, under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License (CC BY NC ND) https://creativecommons.org/licenses/by-nc-nd/4.0/ [119].](https://figures.cochat.ai/paper-figures/c5448ccd6aa14c24a04007d7a6986c4e/the-amyloid-oligomer-hypothesis-beginning-of-the-third-decade-figure-4.jpg)
![Fig.5 Only high-molecular weight AβOs are capable of binding cultured hippocampal neurons. Synthetic AβOs were divided into high and low molecular weight populations using 50 kDa molecular weight cutoff ultrafiltration (A-B) or size exclusion chromatography (D-F) and incubated with cultured hippocampal neurons. Only high-molecular weight AβOs bind neurons (A, E); no binding of low-molecular weight AβOs was evident (B, F). Scale bar = 40μm. Reprinted from “Synaptic targeting by Alzheimer’s-related amyloid beta oligomers” by Lacor PN, Buniel MC, Chang L, Fernandez SJ, Gong Y, Viola KL, Lambert MP, Velasco PT, Bigio EH, Finch CE, Krafft GA, and Klein WL. This was published in J Neurosci, 2004, 24(45): 10191-10200, copyright 2004; permission conveyed through Copyright Clearance Center, Inc. [16].](https://figures.cochat.ai/paper-figures/16de889766c74140a8a5dc196a8cc4d2/the-amyloid-oligomer-hypothesis-beginning-of-the-third-decade-figure-5.jpg)
![Fig.6 PrPc mediates AβO toxicity through mGluR5, Fyn kinase, and NMDARs. Downstream consequences of the pathway include calcium dyshomeostasis, tau hyperphosphorylation, and synaptic dysfunction and loss. Reprinted from “Fyn kinase inhibition as a novel therapy for Alzheimer’s disease” by Nygaard HB, van Dyck CH, and Strittmater SM. This was published in Alzheimers Res Ther, 2014, 6(1): 8, under the terms of the Creative Commons Attribution License (CC BY) [227].](https://figures.cochat.ai/paper-figures/f727ef34b3b345d8b849289bdb182350/the-amyloid-oligomer-hypothesis-beginning-of-the-third-decade-figure-6.jpg)
![Fig.7 AβOs induce membrane re-distribution of NKAα3 subunit resulting its downregulation and excessive Ca++ buildup. A hypothesized early event in AβO-induced neuronal damage is binding to NKAα3 on neuronal membranes, causing restructuring of the NKAα3 docking station into toxic clusters of membrane proteins. Ultimately, this results in downregulation of NKAα3 on the neuronal surface and buildup of toxic Ca++. Adapted and reprinted from “Alzheimer’s Toxic Amyloid Beta Oligomers: Unwelcome Visitors to the Na/K ATPase alpha3 Docking Station” by DiChiara T, DiNunno N, Clark J, Bu RL, Cline EN, Rollins MG, Gong Y, Brody DL, Sligar SG, Velasco PT, Viola KL, and Klein WL. This was published in Yale J Biol Med, 2017, 90(1): 45-61, under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License (CC BY NC ND) https://creativecommons.org/licenses/by-nc-nd/4.0/ [199].](https://figures.cochat.ai/paper-figures/bd05d1a512054c909e16e461e4020c7c/the-amyloid-oligomer-hypothesis-beginning-of-the-third-decade-figure-7.jpg)
![Fig.8 A cumulative hypothesis for the development of sporadic AD. From De Felice, sporadic AD is hypothesized to be the result of the cumulative impact over a life-time of injuries to the brain and peripheral organs that results in increased AβO levels. Reprinted from “Alzheimer’s disease and insulin resistance: translating basic science into clinical applications” by De Felice FG. This was published in JClin Invest, 2013, 123(2): 531-539, under Free access [322].](https://figures.cochat.ai/paper-figures/24020b5bf03e43718e18004cdfcd4325/the-amyloid-oligomer-hypothesis-beginning-of-the-third-decade-figure-8.jpg)
![Fig.9 Putative therapeutic targets of the AβO pathogenic cascade. Including: 1) AβOs themselves; 2) AβO receptors; 3) signaling pathways; or 4) downstream effectors such as tau. Reprinted with permission of PNAS from “Toward a unified therapeutics approach targeting putative amyloid-beta oligomer receptors” by Overk CR and Masliah E. This was published in Proc Natl Acad Sci U S A, 2014, 111(38): 13680-13681 [392].](https://figures.cochat.ai/paper-figures/fd1348f91c8947ff93496ee3a5d93873/the-amyloid-oligomer-hypothesis-beginning-of-the-third-decade-figure-9.jpg)
![Fig.10 Mechanisms of Aβ-targeting phase III drugs in AD clinical trials. Drugs inhibiting AβO formation (A) or downstream consequences of toxic AβOs (B). Reprinted from “Alzheimer’s disease drug development pipeline: 2017” by Cummings J, Garam L, Mortsdorf T, Ritter A, and Zhong K. This was published in Alzheimers Dementia (N Y), 2017, 3(3): 367-384 [393], under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License (CC BY NC ND) https://creativecommons.org/licenses/by-nc-nd/4.0/) [393].](https://figures.cochat.ai/paper-figures/3fe1a59ed5324adab364ba96901a832d/the-amyloid-oligomer-hypothesis-beginning-of-the-third-decade-figure-10.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Soluble Aβ oligomers are the primary neurotoxic substances,131–133”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [131]
The cited source says what the claim attributes to it.
In the citing paper
“Misfolded Aβ and tau proteins accumulate in the AD brain in a neurodegenerative cascade leading to cognitive decline and dementia [4,5,6,7,8,9].”
From Treatment of Alzheimer’s Disease: Beyond Symptomatic Therapies (2023) · cites this paper as [6]
The cited source says what the claim attributes to it.
In the citing paper
“The Aβ oligomer hypothesis, supported by in vitro, in vivo, and ex vivo models, points to the toxic Aβ oligomers rather than amyloid plaques as key players in AD pathogenesis [4,5,6,7].”
From Treatment of Alzheimer’s Disease: Beyond Symptomatic Therapies (2023) · cites this paper as [6]
The cited source says what the claim attributes to it.
In the citing paper
“Elevated levels of oligomers have been associated with AD, as they are found in AD brains and are considered the most toxic and pathogenic form of Aβ [4,5,6,7,18].”
From Treatment of Alzheimer’s Disease: Beyond Symptomatic Therapies (2023) · cites this paper as [6]
In the citing paper
“The alternative “Aβ oligomer hypothesis”, supported by in vitro, in vivo, and ex vivo models, points to the toxic Aβ oligomers (AβO)s rather than amyloid plaques as key players in AD pathogenesis [79,80,81].”
From Role of Oxidative Damage in Alzheimer’s Disease and Neurodegeneration: From Pathogenic Mechanisms to Biomarker Discovery (2021) · cites this paper as [80]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
4 retracted
RETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory
Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., & Ashe, K. H. (2006) · Nature · doi:10.1038/nature04533 · Cited by 2,769
RetractedLarson, M., Sherman, M. A., Amar, F., Nuvolone, M., Schneider, J. A., Bennett, D. A., Aguzzi, A., & Lesné, S. E. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.1858-12.2012 · Cited by 277
RetractedRETRACTED: Cognitive effects of cell-derived and synthetically derived Aβ oligomers
Reed, M. N., Hofmeister, J. J., Jungbauer, L., Welzel, A. T., Yu, C., Sherman, M. A., Lesné, S., LaDu, M. J., Walsh, D. M., Ashe, K. H., et al. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.11.007 · Cited by 131
RetractedAmar, F., Sherman, M. A., Rush, T., Larson, M., Boyle, G., Chang, L., Götz, J., Buisson, A., & Lesné, S. E. (2017) · Science Signaling · doi:10.1126/scisignal.aal2021 · Cited by 112
RetractedAmyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
The amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164 · cited 6×
“dence that AD is a transmissible prion-like disease [5], experimental data support the idea that A Os may spread from cell-to-cell and brain region-toregion in a prion-like manner.”
BackgroundInfluentialAmyloid plaque core protein in Alzheimer disease and Down syndrome.
Masters, C. L., Simms, G., Weinman, N. A., Multhaup, G., McDonald, B. L., & Beyreuther, K. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.12.4245 · Cited by 4,431
Terry, R. D., Masliah, E., Salmon, D. P., Butters, N., DeTeresa, R., Hill, R., Hansen, L. A., & Katzman, R. (1991) · Annals of Neurology · doi:10.1002/ana.410300410 · Cited by 4,397
Meta-Analysis of 74,046 Individuals Identifies 11 New Susceptibility Loci for Alzheimer’s Disease
(EADI), E. A. D. I., Lambert, J.-C., (GERAD), G. A. E. R. I. A. D., Alzheimer's Disease Genetic Consortium (ADGC), (CHARGE), C. F. H. A. A. R. I. G. E., Ibrahim-Verbaas, C. A., Harold, D., Naj, A. C., Sims, R., Bellenguez, C., et al. (2013) · Nature Genetics · doi:10.1038/ng.2802 · Cited by 4,336
Walsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., & Selkoe, D. J. (2002) · Nature · doi:10.1038/416535a · Cited by 4,291
Research works printed but not linked: 4
- Meilandt, 2017, Characterization of the selective in vivo and in vitro binding properties of crenezumab: Insights into crenezumab’s unique mechanism of action, J Prev Alzheimers Dis, 4, 293
- Schneider, 2017, The anti-AB oligomer drug CT1812 for Alzheimer’s: Phase 1B/2A safety trial outcomes, J Prev Alzheimers Dis, 4, 317
- Catalano, 2017, Biomarker outcomes from the phase 1b/2a safety trial of the anti-AB oligomer drug CT1812 in Alzheimer’s patients, J Prev Alzheimers Dis, 4, 401
- Leslie, 2017, Phase II study to assess safety and target engagement of AMX0035, a novel combination therapy, in Alzheimer’s disease, Neurotherapeutics, 14, 825
Cited by
Items 601–700 of 867
Potential benefits of marine-derived compounds for slowing the advancement of Alzheimer’s disease
Malan, A., Choudhary, M., Bamrah, P. K., & kumari, D. (2024) · Journal of Asian Natural Products Research · doi:10.1080/10286020.2024.2409869 · Cited by 5
Samdin, T. D., Kreutzer, A. G., Sahrai, V., Wierzbicki, M., & Nowick, J. S. (2024) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.4c02344 · Cited by 4
Li, S., Li, S., Semdé, R., Teng, H., Shi, M., Huang, L., Lou, X., Jia, B., Zhu, H., & Zhao, Y. (2025) · Chemistry & Biodiversity · doi:10.1002/cbdv.202402771 · Cited by 6
GluN2B of NMDA Receptor and Calmodulin: Balanced Calcium Regulation to Combat Alzheimer's Disease
Tiwari, P. K., Kadiri, S. K., Khobragade, D. S., & Dubey, S. (2025) · Current Drug Therapy · doi:10.2174/0115748855341835250120064444 · Cited by 4
Wei, Q., Liu, D., Xia, W., Wang, F., Huang, L., Zhang, J., Wang, X., Xu, Z., He, C., Li, W., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-60978-w · Cited by 5
Exploring efficient and effective mammalian models for Alzheimer’s disease
Kayano, M. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1652754 · Cited by 4
Exploring Alzheimer’s diseases with focus on diagnostic strategies targeting amyloid beta 42 (Aβ42)
Chauhan, A., Devi, R., Singh, S., Bhutani, K., Prasad, S., Singh, A., Bhaskar, N., Kumar, S., Saini, A. K., & Thakur, R. (2025) · Discover Neuroscience · doi:10.1186/s13064-025-00217-6 · Cited by 6
Tapia-Arellano, A., Palma-Florez, S., Cabrera, P., Cortés-Adasme, E., Bolaños, K., Célis, F., Araya-Vergara, A. J., Pérez, M., Crespo, A., Matus, M. H., et al. (2025) · Materials Today Bio · doi:10.1016/j.mtbio.2025.102453 · Cited by 10
Boeuf, W. L., Hefny, A. A., Karuturi, R. C., & Rao, P. P. N. (2026) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5c00760 · Cited by 5
Wang, Y., Xu, B., Zhou, J., Wang, J., Wang, G., & Cao, Y. (2022) · Acta Neurobiologiae Experimentalis · doi:10.21307/ane-2021-020 · Cited by 5
Self-Assembly of Amyloid Fibrils into 3D Gel Clusters versus 2D Sheets
Karunarathne, K., Bushra, N., Williams, O., Raza, I., Tirado, L., Fakhre, D., Fakhre, F., & Muschol, M. (2023) · Biomolecules · doi:10.3390/biom13020230 · Cited by 4
Molkov, Y. I., Zaretskaia, M. V., Zaretsky, D. V., & Initiative, T. A. D. N. (2023) · Current Alzheimer Research · doi:10.2174/1567205020666230821141745 · Cited by 4
Dastgheib, Z. A., Lithgow, B., & Moussavi, Z. (2023) · Medicina · doi:10.3390/medicina59122091 · Cited by 5
Exploring the Impact of C‐Terminal Based Pentapeptides on the Disassembly of Aβ42 Fibrils
Kaur, A., Mankoo, O. K., Rani, D., Priyadarshi, N., Goyal, D., Singhal, N. K., & Goyal, B. (2024) · ChemMedChem · doi:10.1002/cmdc.202400486 · Cited by 5
Nakano, H., Hikishima, S., Mori, M., Minamikawa, J., Muramatsu, D., Sakashita, Y., Ikeda, T., Noguchi‐Shinohara, M., Teplow, D. B., & Ono, K. (2024) · Neurobiology of Disease · doi:10.1016/j.nbd.2024.106775 · Cited by 4
Johnson, E. A., Nowar, R., Viola, K. L., Huang, W., Zhou, S., Bicca, M. A., Zhu, W., Kranz, D. L., Klein, W. L., & Silverman, R. B. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2402117122 · Cited by 5
Self-citationKola, A., Costanti, F., Kahfi, J., Emwas, A.-H. M., Jaremko, M., & Valensin, D. (2025) · Cells · doi:10.3390/cells14070525 · Cited by 5
Lee, R., Kim, G., Black, E. R., & Kim, S. (2026) · Advanced Science · doi:10.1002/advs.77858 · Cited by 5
Trumbore, C. N. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-171080 · Cited by 4
Clusterin inhibits Aβ42 aggregation through a “strawberry model” as detected by FRET‐FCS
Xu, L., Tian, S., Peng, X.-L., Hua, Y., Yang, W., Chen, L., Liu, S., Wu, W., Zhao, J., He, J., et al. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15344 · Cited by 4
Molecular packing of lipid membranes and action mechanisms of membrane-active peptides
Chiou, P.-C., Hsu, W.-W., Chang, Y., & Chen, Y. (2022) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2022.112384 · Cited by 6
Patta, P. C., de Oliveira, E. M. N., Goulart, A. C. F., Zaluski, A. B., Papaléo, R. M., & Vianna, M. R. M. R. (2022) · Neuroscience · doi:10.1016/j.neuroscience.2022.02.031 · Cited by 5
Effect of carbonaceous ultrafine particles on the structure and oligomerization of Aβ42 peptide
Kaumbekova, S., Torkmahalleh, M. A., Umezawa, M., Wang, Y., & Shah, D. (2023) · Environmental Pollution · doi:10.1016/j.envpol.2023.121273 · Cited by 5
Song, C., Li, H., Zheng, C., Zhang, T., & Zhang, Y. (2023) · Molecular Neurobiology · doi:10.1007/s12035-023-03406-8 · Cited by 5
Sterol-activated amyloid beta fibril formation
Cook, I. T., & Leyh, T. S. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.105445 · Cited by 6
Computational Study on Structure and Aggregation Pathway of Aβ42 Amyloid Protofibril
Lee, M., Yoon, J., & Shin, S. (2019) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.9b07195 · Cited by 4
Man, V. H., Lin, D., He, X., Gao, J., & Wang, J. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220450 · Cited by 4
Corraliza-Gómez, M. (2021) · UVaDOC UVaDOC University of Valladolid Documentary Repository (University of Valladolid) · doi:10.35376/10324/51889 · Cited by 6
Structural Model for Self-Limiting β-strand Arrangement Within an Alzheimer’s Amyloid-β OligomerPreprint
Gao, Y., Prasad, R., Randolph, P. S., Watzlawik, J. O., Robang, A. S., Guo, C., Stagg, S. M., Zhou, H., Rosenberry, T. L., & Paravastu, A. K. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.12.06.519347 · Cited by 4
Maladies neurodégénératives et stress oxydant
Lévy, E. (2020) · theses.fr (ABES) · doi:10.70675/75371581z194fz4cb4zb457z91bf72dc0320 · Cited by 4
Predicting biological age using an accumulated neurotoxicity biomarker for amyloid beta oligomers
Kuznetsov, A. V. (2026) · Mathematical Medicine and Biology A Journal of the IMA · doi:10.1093/imammb/dqag005 · Cited by 4
A genetically encoded selection for amyloid-β oligomer binders
Lee, B., Mannone, J. A., & Wang, T. (2025) · Nature Chemical Biology · doi:10.1038/s41589-025-01975-4 · Cited by 3
Athanasaki, A., Tsantzali, I., Theodorou, A., Michalopoulou, A., Constantinides, V. C., Boufidou, F., Tzartos, J. S., Tsalouchidou, P., Zompola, C., Paraskevas, S. G., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26199531 · Cited by 4
Xie, D., Zheng, Q., Lv, J., Zhang, Q., Cui, Z., Huang, S., Yu, W., Chen, B., Que, W., Fu, S., et al. (2025) · Advanced Science · doi:10.1002/advs.202510270 · Cited by 3
Staneva, G., Yordanova, V., Danailova, A., Marinovska, A.-M., Dér, A., & Taneva, S. G. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262311361 · Cited by 3
Pandey, S., Danielsen, M. B., Xiang, Y., Zhang, Z., Sharma, G., Jeon, B. T., Song, S., Hao, Y., Zhang, G., Christensen, N. J., et al. (2024) · Cell Reports Physical Science · doi:10.1016/j.xcrp.2024.102336 · Cited by 4
Kashiyama, R., Watanabe, H., Akasaka, T., & Ono, M. (2025) · Dyes and Pigments · doi:10.1016/j.dyepig.2025.112680 · Cited by 3
Ruthenium(II)–Arene Complexes with a 2,2′-Bipyridine Ligand as Anti-Aβ Agents
Hacker, R. M., Smith, J. J., Platt, D. C., Brennessel, W. W., Jones, M. A., & Webb, M. I. (2025) · Biomolecules · doi:10.3390/biom15040475 · Cited by 3
Varoglutamstat Inhibits the Dimerization of the Aβ25–35 Fragment in Aqueous Solution
Nguyen, H. A., Nguyen, T. H., Vu, V. V., Derreumaux, P., & Ngo, S. T. (2025) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.5c03306 · Cited by 3
Kavitha, J. M., Sindhu, K. S., & Abi, T. G. (2025) · Computational and Theoretical Chemistry · doi:10.1016/j.comptc.2025.115486 · Cited by 3
Bergo, N. J., Lee, S., Siebrand, C. J., Mayeri, Z., Andersen, J. K., & Walton, C. C. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-07324-2 · Cited by 4
Polyphenols as Potential Therapeutic Drugs in Neurodegeneration
de Laureto, P. P., Palazzi, L., & Acquasaliente, L. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.89575 · Cited by 4
The role of hydrophobic collapse in cytotoxic and functional amyloid oligomerization
King, K. M., Zaheer, H., & Brown, A. M. (2025) · Biophysical Journal · doi:10.1016/j.bpj.2025.07.042 · Cited by 4
Camins, A., Ettcheto, M., & Busquets, O. (2019) · Neural Regeneration Research · doi:10.4103/1673-5374.257513 · Cited by 3
Zou, D., Li, Q., Pan, W., Chen, P., Sun, M., & Bao, X. (2022) · Molecular Medicine Reports · doi:10.3892/mmr.2022.12669 · Cited by 4
Wang, S., Kang, D. W., Um, Y. H., Kim, S., Lee, C. U., Scheltens, P., & Lim, H. K. (2023) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2023.87 · Cited by 4
Risk of Dementia in Patients with Leptospirosis: A Nationwide Cohort Analysis
Chiu, C.-H., Chen, P.-C., Wang, Y.-C., Lin, C., Lee, F.-Y., Wu, C., & Chang, K. (2019) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph16173168 · Cited by 7
Dokoohaki, M. H., Zolghadr, A. R., & Klein, A. (2019) · New Journal of Chemistry · doi:10.1039/c9nj04251b · Cited by 3
Romanova, L. G., Phillips, H., Calip, G. S., Hauser, K., Peterson, D. A., Lazarov, O., Predescu, D., Predescu, S. A., Schneider, J. A., Kordower, J. H., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/427617 · Cited by 3
Shea, Y. F., & DeKosky, S. T. (2020) · Springer eBooks · doi:10.1007/978-3-319-69892-2_665-1 · Cited by 3
Editorial: Beta-Amyloid oligomer specific treatments for Alzheimer's disease
Hillen, H. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1034158 · Cited by 3
Han, X., Li, P. H., Wang, S., Blakely, T. M., Aggarwal, S., Gopalani, B., Sanchez, M., Schalek, R. L., Meirovitch, Y., Lin, Z., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.10.24.563674 · Cited by 5
Inhibitory effects of extracts from Eucalyptus gunnii on α-synuclein amyloid fibrils
So, M., Ono, M., Oogai, S., Kondo, M., Yamazaki, K., Nachtegael, C., Hamajima, H., Mutoh, R., Kato, M., Kawate, H., et al. (2024) · Bioscience Biotechnology and Biochemistry · doi:10.1093/bbb/zbae114 · Cited by 2
Understanding the pathophysiology of alzheimer's disease: Insights for early diagnosis
Alharbi, S. S., Alharbi, S. S., Alanazi, A. F., & Alomran, R. W. (2022) · International Journal of Health Sciences · doi:10.53730/ijhs.v6ns10.15185 · Cited by 2
Sousa, R. A. L. D., & Mendes, B. F. (2024) · Brain Research · doi:10.1016/j.brainres.2024.149393 · Cited by 5
Riffo-Lepe, N., González-Sanmiguel, J., Armijo‐Weingart, L., Saavedra, P., Hernandez, D., Ramos, G., Martín, L. S., & Aguayo, L. G. (2025) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-24-01052 · Cited by 7
Dabas, A., & Goyal, B. (2025) · Physical Chemistry Chemical Physics · doi:10.1039/d4cp03330b · Cited by 2
Asada, T., Kakuma, T., Tanaka, M., Araki, W., Lebowitz, A., Momose, T., & Matsuda, H. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251324222 · Cited by 2
Aortic Stiffness and Alzheimer’s Disease: The Medin Connection
Triposkiadis, F. K., Xanthopoulos, A. V., Boudoulas, H. K., & Brutsaert, D. L. (2025) · Biomolecules · doi:10.3390/biom15081148 · Cited by 2
Saavedra, J., Nascimento, M., Figueira, A. J., da Silva, M. I. O., Gião, T., Oliveira, J. F., Liz, M. A., Gomes, C. M., & Cardoso, I. (2025) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2025.1636365 · Cited by 2
Sajimon, M., Wheeler, C. J., Foley, A. R., Chan, K., Griffin, M. N., Dinakarapandian, D. M., Holberton, A. L., Joy, J., Paravastu, A. K., Wood, L. B., et al. (2025) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5c00544 · Cited by 3
Kranz, D. L., Velez, O. D. L., Ulupınar, E., Özdinler, P. H., Silverman, R. B., & Klein, W. L. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70968 · Cited by 3
Self-citationXie, P., Wang, X., Wang, H., Xue, H., He, S., Li, L., Wong, M. S., & Qiao, X. G. (2026) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2026.118430 · Cited by 3
Senkowska, Z., & Węglarz‐Tomczak, E. (2026) · Ageing Research Reviews · doi:10.1016/j.arr.2026.103116 · Cited by 2
Lee, B., Flood, B., Potter, E., & Wang, T. (2026) · ChemBioChem · doi:10.1002/cbic.202500908 · Cited by 2
Nurmakova, K., Gomes, G.-N. W., & Levine, Z. A. (2026) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2026.113494 · Cited by 2
African green monkeys respond to synthetic Aβ oligomers with persistent Alzheimer’s-like activation
Brown, B. R. P., Li, X., Grasty, M. R., Lopez, I. R., Dzigurski, S., Geradi, M. N., Weed, M. R., Elsworth, J. D., Lawrence, M. S., Gürsoy, G., et al. (2026) · Communications Biology · doi:10.1038/s42003-026-10968-5 · Cited by 2
Cognitive Dysfunction and Diabetes
Jung, C., & Mok, J. (2022) · Journal of Korean Diabetes · doi:10.4093/jkd.2022.23.3.165 · Cited by 3
Addabbo, R. M., Hutchinson, R. B., Allaman, H. J., Dalphin, M. D., Mecha, M. F., Liu, Y., Staikos, A., & Cavagnero, S. (2023) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.2c08485 · Cited by 2
Jehangir, M., Wang, X., Zhao, Y., Ali, U., kashmiri, K., & cheng, W. (2024) · World Journal of Advanced Research and Reviews · doi:10.30574/wjarr.2024.23.2.2349 · Cited by 2
Treatment of Alzheimer’s disease by promoting the aggregation of small β-amyloid peptides
JiWei, M. A. I., ZHANG, J., & Dou, F. (2022) · Scientia Sinica Vitae · doi:10.1360/ssv-2022-0143 · Cited by 2
Differentiation of subnucleus-sized oligomers and nucleation-competent assemblies of the A β peptide
Pauly, T. A., Zhang, T., Sternke‐Hoffmann, R., Nagel‐Steger, L., & Willbold, D. (2022) · Biophysical Journal · doi:10.1016/j.bpj.2022.12.020 · Cited by 2
Zhu, J., Kreutzer, A. G., Liu, Z., Li, X., Richter, S. M., Pophristic, V., & Nowick, J. S. (2025) · Organic & Biomolecular Chemistry · doi:10.1039/d5ob00296f · Cited by 2
The Framework for an Integrative Theory of Alzheimer’s Disease
Zaretsky, D. V., & Zaretskaia, M. V. (2025) · Current Alzheimer Research · doi:10.2174/0115672050381553250425062803 · Cited by 2
Intrinsic visible emission of amyloid-β oligomers: a potential tool for early alzheimer's diagnosis
Novo, M., Illodo, S., Seijas, J., Hernández, S., Rodríguez‐Prieto, F., & Al‐Soufi, W. (2025) · Physical Chemistry Chemical Physics · doi:10.1039/d5cp01547b · Cited by 2
The Influence of POPC as a Coaggregate in Amyloid-β Oligomer Formation
King, K. M., Cleveland, E. M., Pennington, A., Fuccello, S., & Brown, A. M. (2025) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5c00605 · Cited by 2
Gu, X., Yu, S. P., Jiang, M. Q., Zhong, W., Sastry, A., & Wei, L. (2025) · Neuroscience Bulletin · doi:10.1007/s12264-025-01525-x · Cited by 2
Tammara, V., & Das, A. (2022) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.26436 · Cited by 2
Generation and study of antibodies against two triangular trimers derived from Aβ
Kreutzer, A. G., Malonis, R. J., Parrocha, C. M. T., Tong, K., Guaglianone, G., Nguyen, J. T., Diab, M. N., Lai, J. R., & Nowick, J. S. (2023) · Peptide Science · doi:10.1002/pep2.24333 · Cited by 3
Potential role of nobiletin in Alzheimer’s disease
Fang, H., Zhang, L., & Zhao, H. (2023) · Journal of Food Bioactives · doi:10.31665/jfb.2023.18361 · Cited by 2
Ahyayauch, H., Masserini, M., Goñi, F. M., & Alonso, A. (2024) · Biomolecules · doi:10.3390/biom14030298 · Cited by 2
Roberts, C. F., Cao, Y., Im, W., Nichols, R. A., Lukas, R. J., & George, A. A. (2024) · British Journal of Pharmacology · doi:10.1111/bph.16381 · Cited by 2
Synaptic Oligomers and Glial Cells in Alzheimer Disease
Grinberg, L. T. (2023) · JAMA Neurology · doi:10.1001/jamaneurol.2023.3539 · Cited by 2
Wu, J., Zhang, Z., Pulgar, I. M. R., Jiang, S., Wang, P., Chai, K., Pathak, A. P., Oishi, K., Li, Y., Bang, J., et al. (2025) · Magnetic Resonance in Medicine · doi:10.1002/mrm.70122 · Cited by 1
Umbilical Cord-Derived Cells: Applications in Neurological Disorders
Vasques, J. F., Chimeli-Ormonde, L., Gubert, F., Méndez‐Otero, R., & Pimentel‐Coelho, P. M. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-15717-2.00003-2 · Cited by 1
Chen, A., Shea, D. W., & Daggett, V. (2024) · Scientific Reports · doi:10.1038/s41598-024-57107-w · Cited by 1
Monoclonal antibody therapy in Alzheimer’s disease: an overview and vision
Bentley, J. H., Bishop, L. E., & Broussard, J. I. (2024) · Brain Network and Modulation · doi:10.4103/bnm.bnm_14_23 · Cited by 2
Dietz, L. T., Põld, K., Györffy, B. A., Zharkovsky, A., Sørensen, J. B., Pankratova, S., & Dmytriyeva, O. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04475-z · Cited by 2
3-N-Butylphthalide alleviate Aβ-induced cellular senescence through the CDK2-pRB1-Caspase3 axis
Tian, Y., Li, W., & Zhang, Y. (2024) · Brain Research · doi:10.1016/j.brainres.2024.149435 · Cited by 1
Yokoyama, K., Mukkatt, J., Mathewson, N., Fazzolari, M. D., Hackert, V., Ali, M. M., Monichan, A. C., Wilson, A. J., Durisile, B. C., & Neuwirth, L. S. (2025) · Neuroscience Letters · doi:10.1016/j.neulet.2025.138218 · Cited by 1
Harada, C., Matsui, A., Irie, Y., Uchino, A., Chikugo, A., Fujii, K., Hosoi, K., Nakanishi, A., Kageyama, Y., Naruse, N., et al. (2025) · Chemical Communications · doi:10.1039/d5cc00856e · Cited by 1
Матухно, А. Е., Tkacheva, P. V., Voinov, V. B., Lysenko, L. V., Evsyukova, E. V., Taisaeva, A. O., & Борисович, Б. И. (2025) · Neuroscience and Behavioral Physiology · doi:10.1007/s11055-025-01811-1 · Cited by 1
Vegas‐Gomez, L., Pizarro, M., Garcia-Martin, J., Arredondo-Alcala, M. A., Bustamante, B., Gonzalez‐Silva, C., Matus, S., Díaz‐Espinoza, R., Gutiérrez, A., Morales, R., et al. (2025) · PLoS ONE · doi:10.1371/journal.pone.0328470 · Cited by 2
Hernández, S., Valladares‐Rodríguez, S., Novo, M., & Al‐Soufi, W. (2025) · Journal of dementia and Alzheimer's disease · doi:10.3390/jdad2040038 · Cited by 2
Man, V. H., He, X., Nguyen, P. H., Gao, J., & Wang, J. (2025) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5c00734 · Cited by 1
Chronobiology and Neurodegeneration: The Role of Melatonin in Alzheimer's Disease
Vaja, R., Vohra, M., Ramachandran, A. V., & Baxi, D. B. (2025) · Nutritional Psychiatry · doi:10.1016/j.nupsyc.2025.100001 · Cited by 2
Guidotti, L., Lucchesi, M., Daghini, E., Amato, R., Neri, G., Corsi, F., Marracci, S., Gargini, C., Borello, U., Cammalleri, M., et al. (2026) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.67.2.31 · Cited by 1
Synthesis, Radiochemistry, and Preclinical Assessment of the First GPR39 PET Imaging Agent
Bhoopal, B., Gollapelli, K. K., Damuka, N., Krizan, I. M., Miller, M. D., Fitzgerald, R. W., Amesar, N., Mumbaraddi, D., Zhu, D., Cervera‐Juanes, R. P., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c03351 · Cited by 2
Napolitano, L., Vadukul, D. M., Bigi, A., Palladino, P., Cecchi, C., Chiti, F., Cascella, R., & Aprile, F. A. (2026) · Communications Biology · doi:10.1038/s42003-026-09740-6 · Cited by 2
Malpani, P., Rana, M., Morda, U., & Sharma, A. K. (2026) · ChemistrySelect · doi:10.1002/slct.202504275 · Cited by 1
Metadata
- Authors
- Cline, E. N., Bicca, M. A., Viola, K. L., & Klein, W. L.
- Affiliations
- Northwestern University (US)
- Department of Neurobiology, Cognitive Neurology and Alzheimer’s Disease Center, International Institute for Nanotechnology, and Chemistry of Life Processes Institute, Northwestern University, Evanston, IL, USA
- Corresponding author
- Klein, William L.
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2018-06-12
- Volume
- 64
- Issue
- s1
- Pages
- S567-S610
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- PMC
- PMC6004937
- OpenAlex
- W2809078375
- Cited by
- 870
- References
- 457
- Citations by year
- 2026: 72 · 2025: 109 · 2024: 99 · 2023: 133 · 2022: 123 · 2021: 123 · 2020: 119 · 2019: 74 · 2018: 17
- FWCI
- 10.99
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Alzheimer s Disease (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- National Institute on Aging (R41AG054337, T32AG020506)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- amyloid-beta oligomers, Alzheimer's disease
- MeSH terms
- Alzheimer Disease, Animals, Humans, Models, Neurological, Amyloid beta-Peptides
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.